Mesoblast (ASX:MSB) shares have plunged by a third after the US Food and Drug Administration asked the biotech company to … Read More
The post Mesoblast plunges after US FDA requires new trial appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.